ImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial Success

ImmunityBio, Inc. (NASDAQ:IBRX) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. With a price target of $8, H.C. Wainwright analysts reiterated their Buy rating on ImmunityBio, Inc. (NASDAQ:IBRX) on June 4. The decision comes after the company’s recent regulatory triumphs, which include the FDA’s Expanded Access authorization for its Cancer BioShield platform this month and the RMAT designation it received in February.

The Cancer BioShield platform, which addresses immune collapse in malignancies that prove difficult to treat, is anchored by ANKTIVA and PD-L1 t-haNK CAR-NK cells. In that regard, ImmunityBio, Inc. (NASDAQ:IBRX) provided evidence at the ASCO 2025 conference that ANKTIVA (N-803), an IL-15 superagonist, is the first authorized lymphocyte-stimulating drug that can reverse treatment-induced lymphopenia.

In a Phase 2 QUILT-88 study, ANKTIVA, SBRT, PD-L1 t-haNK cells, and low-dose chemotherapy together demonstrated an increase in survival associated with immune restoration in 86 patients with advanced pancreatic cancer. Given that more than 77% of trial participants saw immune recovery, the analysts underlined the importance of these results and pointed out that ANKTIVA is a novel strategy for treating immune system collapse.

ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company committed to developing novel cancer treatments by using cellular immunotherapy, which targets cancer cells by utilizing the body’s immune system.

While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.